Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Nucleotide changes within an exon can alter the trinucleotide normally encoding a particular amino acid, such that a new ‘‘stop’’ signal is transcribed into the mRNA open reading frame. This causes the ribosome to prematurely terminate its reading of the mRNA, leading to nonsense-mediated decay of the transcript and lack of production of a normal full-length protein. Such premature termination codon mutations occur in an estimated 10% to 15% of many genetically based disorders, including Duchenne/ Becker muscular dystrophy. Therapeutic strategies have been developed to induce ribosomal read-through of nonsense mutations in mRNA and allow production of a full-length functional protein. Small-molecule drugs (aminoglycosides and ataluren [PTC124]) have been developed and are in clinical testing in patients with nonsense mutations within the dystrophin gene. Use of nonsense mutation suppression in Duchenne/Becker muscular dystrophy may offer the prospect of targeting the specific mutation causing the disease and correcting the fundamental pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667 · cited 1×
“A small subset of patients is classified as having Becker muscular dystrophy, a phenotypically milder form in the continuum of the disease that is usually associated with a later manifestation of symptoms and a slower rate of decline in motor, respiratory, and cardiac function.(2) Patients with Duchenne muscular dystr…”
BackgroundDystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Influence of codon context on UGA suppression and readthrough
Kopelowitz, J., Hampe, C., Goldman, R., Reches, M., & Engelberg-Kulka, H. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90920-f · Cited by 67 · cited 1×
“The neighboring nucleotide appears to be important to the context of how the nonsense mutation is interpreted by the ribosome.(18) A UGA trinucleotide nonsense mutation appears to be the most permissive, in an in vitro setting, whereas a UAA is the most stringent.”
Background
Cited by
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Therapeutics Based on Stop Codon Readthrough
Keeling, K. M., Xue, X., Gunn, G., & Bedwell, D. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153527 · Cited by 306
“In contrast to those negative results, numerous other in vitro studies found that PTC124 suppresses nonsense mutations and restores deficient protein function associated with numerous disorders, including MPS VI (9), MPS I-H (100), Usher syndrome (47, 48), infantile neuronal ceroid lipofuscinosis (119), propionic acid…”
InfluentialGlobal Genetic Networks and the Genotype-to-Phenotype Relationship
Costanzo, M., Kuzmin, E., van Leeuwen, J., Mair, B., Moffat, J., Boone, C., & Andrews, B. (2019) · Cell · doi:10.1016/j.cell.2019.01.033 · Cited by 241
“Indeed, in certain genetic disorders, such as Duchenne muscular dystrophy, treatment options are focused on increasing translation of the disease-associated mutant mRNA (Finkel, 2010).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Neu-Yilik, G., Amthor, B., Gehring, N. H., Bahri, S., Paidassi, H., Hentze, M. W., & Kulozik, A. E. (2011) · RNA · doi:10.1261/rna.2401811 · Cited by 140
Metadata
- Authors
- Finkel, R. S.
- Venue
- Journal of Child Neurology
- Publisher
- SAGE Publications
- Published
- 2010-06-02
- Volume
- 25
- Issue
- 9
- Pages
- 1158-1164
- ISSN
- 0883-0738 (ISSN-L)
- 1708-8283
- OpenAlex
- W1964630716
- Cited by
- 161
- References
- 5
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124). https://app.cochat.ai/papers/10.1177/0883073810371129
- The paper
- Finkel, R. S. (2010). Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124). Journal of Child Neurology. https://doi.org/10.1177/0883073810371129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.